42.97
+0.84%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Teva Pharma Industries Ltd ADR
From its filings with the US Securities and Exchange Commission
Teva Pharma Industries Ltd ADR is based in Tel Aviv and is incorporated in Israel. Its shares trade on NYSE under the ticker TEVA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported net income of $1.41bn. At that date it held total assets of $40.75bn and shareholders' equity of $7.91bn.
We are a biopharmaceutical company, enabled by a world-class generics business. For over 120 years, our commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, we are dedicated to addressing patients’ needs, now and in the future.
We operate worldwide, with headquarters in Israel and a significant presence in the United States, Europe and many other markets around the world. Today, our global network of capabilities consists of approximately 34,000 employees across 57 markets.
Teva was incorporated in Israel on February 13, 1944 and is the successor to a number of Israeli corporations, the oldest of which was established in 1901.
We operate our business through three segments: United States, Europe and International Markets. Each business segment manages our entire product portfolio in its region, including generics, which includes biosimilars and over-the-counter (“OTC”) products, as well as innovative medicines. This structure enables strong alignment and integration between operations, commercial regions, R&D, and our global marketing and portfolio function, optimizing our product lifecycle across therapeutic areas.
Quoted from its 10-K, filed 3 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 26 Mar 1990
- Employees
- 34,000
- Website
- tevapharm.com ↗
- Head office
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
- Incorporated in
- L3
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Teva Pharma Industries Ltd ADR has a global presence with operations in the US, Europe, Israel, and internationally.
- The company offers a diverse portfolio including generic medicines, biopharmaceutical products, and medical devices.
- Teva provides specialized treatments such as BENDEKA, TREANDA, COPAXONE, AJOVY, and AUSTEDO for specific medical conditions.
Weaknesses
- The company's operations are heavily reliant on the pharmaceutical industry, which is subject to regulatory changes.
- Teva's focus on generic medicines may limit its ability to innovate compared to branded drug manufacturers.
- The company's website is provided as a source but is treated as untrusted, indicating potential issues with information reliability.
Opportunities
- Expanding into new markets for generic and biopharmaceutical products could increase market share.
- Growing demand for treatments in CNS, respiratory, and oncology areas presents opportunities for product development.
- The out-licensing platform could attract partnerships with other pharmaceutical companies for mutual growth.
Threats
- Regulatory changes in the pharmaceutical industry could impact product approvals and market access.
- Competition from other generic drug manufacturers may reduce profit margins.
- The reliance on specific product lines like COPAXONE and AJOVY could be vulnerable to patent expirations or generic competition.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.